CHARACTERISTIСS OF THE LIPID PROFILE AT PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED WITH STEATOSIS
https://doi.org/10.21886/2219-8075-2013-3-56-59
Abstract
Purpose: To study dynamics of a lipidic profile at patients with diabetes 2 types, against combination application of exenatide and metformin.
Materials and methods: Research is conducted on 87 patients with diabetes 2 types complicated steatosis. All patients received general clinical research such as lipidogram.
Results: In the course of treatment patients had a decrease in atherogenous fractions of the cholesterol, more expressed at treatment metformin and combinations metformin with the exenatide. The combination metformin with preparations sulfonylurea concerning correction of indicators of a lipidic exchange was less effective.
Summary: more effective constrain hypertriglyceridemia as a risk factor for steatosis observed with metformin and exenatide.
About the Authors
N. A. Kuzmenko
Rostov State Medical University
Russian Federation
Russian Federation
Department of endocrinology with a course of children’s endocrinology
29 Nakhichevansky st., Rostov-on-Don, 344022A. S. Sultanmuradova
Rostov State Medical University
Russian Federation
Russian Federation
Department of endocrinology with a course of children’s endocrinology
29 Nakhichevansky st., Rostov-on-Don, 344022References
1. Шестакова М.В., Викулова О.К. Современные возможности фармакотерапии сахарного диабета 2 типа при помощи аналогов глюкагоноподобного пептида-1 (ГПП-1)// Сахарный диабет.- 2007.- №1.- С.9-15.
2. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N.,David E., Rizzetto M., Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease // Am. J. Gastroenterol. – 2005. – 100. – P. 1082–90.
3. Lin Y.C., Lo H.M., Chen J.D. Sonographic fatty liver, overweight and ischemic heart disease // World J. Gastroenterol. – 2005. – 11. – P. 4838–4842.
4. Анциферов М.Б., Дорофеева Л.Г. Инкретиномиметики в терапии сахарного диабета 2-го типа// Леч. врач.- 2009.- №3.– С.14- 21.
5. Джанашия П.Х., Мирина Е.Ю. // РМЖ. -2008. –Т.16. -№11. – С.1156-1567.
6. Garcia–Caballero M., Tinahones F.J., Cohen R.V. Diabetes surgery – 2010 – 374 с.
7. Nichols G.A., et al. Am. J. Med. 2008; 121: 519—524.
8. Шилов А.М., Авшалумов А.Ш., Марковский В.Б., Е.Н. Синицина Е.Н. и соавт. Тактика лечения дислипидемий при метаболическом синдроме: статины или фибраты?//Фарматека – 2009.- № 6.- С.93-98
9. Дедов И.И. Проблема ожирения: от синдрома к заболеванию. // Ожирение и метаболизм. - 2006. - №1(6). - С.2–4.
10. Гинзбург М.М., Крюков Н.Н.. Ожирение. Влияние на развитие метаболического синдрома. Профилактика и лечение. М.: Медпрактика – М. – 2002 – 128 с.
11. Дедов И.И., Мельниченко Г.А., Романцова Т.И. // Ожирение и метаболизм. – 2004. – Т.3, №6. – С.84– 89.
Review
For citations:
Kuzmenko N.A., Sultanmuradova A.S. CHARACTERISTIСS OF THE LIPID PROFILE AT PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED WITH STEATOSIS. Medical Herald of the South of Russia. 2013;(3):56-59. (In Russ.) https://doi.org/10.21886/2219-8075-2013-3-56-59
Views:
451
Email this article 